Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? | The Pharmacogenomics Journal
Pisa, 2 Ottobre 2018
Therapeutic Route-map for a Successful Treatment of melanoma - Pisa 2 ottobre 2018
Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana
Le meraviglie… nel paese di Alice': lo spettacolo con protagonisti medici, infermieri e pazienti - gonews.it
How to get to Studio Veterinario Fisioterapia Dr. Clelia Bargagli Stoffi in Pisa by Bus or Train?
Periodico bimestrale dell'Ordine dei Medici e degli Odontoiatri della provincia di Pisa
خلف لمح إقامة polo oncologico pisa - buddhabirthplace.net
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorect
Biosimilar pegfilgrastim and adherence to guidelines for chemotherapy-induced neutropenia and infections in cancer patients
PDF) Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest | Gianluca Tomasello - Academia.edu
Frontiers | Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial | Oncology
Study in English at the University of Pisa
Untitled
Carcinoma colorettale: linee di ricerca, innovazioni e sfide future. Congresso a Pisa - insalutenews.it
PDF) Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in large cell neuroendocrine carcinoma
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in pati
Fondazione Arco | una freccia in più al nostro arco
CANCER METRONOMIC THERAPY GASTROINTESTINAL CANCERS
How the Lab is Changing Our View of Colorectal Cancer
Incontri al Polo Oncologico di Pisa - Pane e parole
Tumori: a Pisa il primo punto servizi per i pazienti oncologici in Toscana - intoscana
Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience
Onco Corner
